http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 14 Jan 2026 10:21:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Eagle+Pharmaceuticals+Announces+Divestiture+of+Barhemsys/25848201.html <p align="justify">WOODCLIFF LAKE, N.J., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the divestiture of the marketing authorization for Barhemsys (amisulpride) in the U.S. to LXO Group, Paris, France.</p> <p align="justify">Barhemsys is used for the treatment of Postoperative Nausea and Vomiting (PONV) alone or with another antiemetic in patients with or without prior prophylaxis. Approved in February 2020 and launched in the U.S. in November 2020, Barhemsys is the only FDA-approved treatment for PONV, addressing a critical need in post-surgical care by offering a targeted, effective http://www.streetinsider.com/Press+Releases/Eagle+Pharmaceuticals+Announces+Divestiture+of+Barhemsys/25848201.html Wed, 14 Jan 2026 10:21:00 -0500 EGRX O.00073296 http://www.streetinsider.com/Press+Releases/Eagle+Pharmaceuticals+Announces+Divestiture+of+Barhemsys/25848201.html <p align="justify">WOODCLIFF LAKE, N.J., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the divestiture of the marketing authorization for Barhemsys (amisulpride) in the U.S. to LXO Group, Paris, France.</p> <p align="justify">Barhemsys is used for the treatment of Postoperative Nausea and Vomiting (PONV) alone or with another antiemetic in patients with or without prior prophylaxis. Approved in February 2020 and launched in the U.S. in November 2020, Barhemsys is the only FDA-approved treatment for PONV, addressing a critical need in post-surgical care by offering a targeted, effective http://www.streetinsider.com/Press+Releases/Eagle+Pharmaceuticals+Announces+Divestiture+of+Barhemsys/25848201.html Wed, 14 Jan 2026 10:21:00 -0500 EGRX O.00073296 http://www.streetinsider.com/Globe+Newswire/Eagle+Pharmaceuticals+Announces+Divestiture+of+Barhemsys/25848201.html <p align="justify">WOODCLIFF LAKE, N.J., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the divestiture of the marketing authorization for Barhemsys (amisulpride) in the U.S. to LXO Group, Paris, France.</p> <p align="justify">Barhemsys is used for the treatment of Postoperative Nausea and Vomiting (PONV) alone or with another antiemetic in patients with or without prior prophylaxis. Approved in February 2020 and launched in the U.S. in November 2020, Barhemsys is the only FDA-approved treatment for PONV, addressing a critical need in post-surgical care by offering a targeted, effective http://www.streetinsider.com/Globe+Newswire/Eagle+Pharmaceuticals+Announces+Divestiture+of+Barhemsys/25848201.html Wed, 14 Jan 2026 10:21:00 -0500 EGRX O.00073296 http://www.streetinsider.com/Globe+Newswire/Eagle+Pharmaceuticals+Announces+Divestiture+of+Barhemsys/25848201.html <p align="justify">WOODCLIFF LAKE, N.J., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the divestiture of the marketing authorization for Barhemsys (amisulpride) in the U.S. to LXO Group, Paris, France.</p> <p align="justify">Barhemsys is used for the treatment of Postoperative Nausea and Vomiting (PONV) alone or with another antiemetic in patients with or without prior prophylaxis. Approved in February 2020 and launched in the U.S. in November 2020, Barhemsys is the only FDA-approved treatment for PONV, addressing a critical need in post-surgical care by offering a targeted, effective http://www.streetinsider.com/Globe+Newswire/Eagle+Pharmaceuticals+Announces+Divestiture+of+Barhemsys/25848201.html Wed, 14 Jan 2026 10:21:00 -0500 EGRX O.00073296 http://www.streetinsider.com/Earnings/Eagle+Pharmaceuticals+%28EGRX%29+Reports+Q2+Loss+of+%240.12/25466693.html <p>Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of ($0.12). Revenue for the quarter came in at $48.71 million versus the consensus estimate of $53.87 million.</p><p>For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) <a href="http://www.streetinsider.com/ec_earnings.php?q=EGRX">click here</a>.</p> http://www.streetinsider.com/Earnings/Eagle+Pharmaceuticals+%28EGRX%29+Reports+Q2+Loss+of+%240.12/25466693.html Thu, 16 Oct 2025 16:20:47 -0500 EGRX http://www.streetinsider.com/Press+Releases/Eagle+Pharmaceuticals+Announces+Availability+of+Proxy+Materials+and+Audited+Financial+Statements+for+the+2023+and+2024+Fiscal+Years/25346502.html <p align="justify">WOODCLIFF LAKE, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced the availability of proxy materials for its 2025 Annual Meeting of Stockholders, which is scheduled to be held virtually on October 17, 2025 at 10:00 a.m. Eastern Time.</p> <p align="justify">The Company is delivering a Notice of Internet Availability of Proxy Materials (“Notice”) to stockholders of record as of the close of business on August 18, 2025. The proxy materials relating to the 2025 Annual Meeting of Stockholders, including the Notice, proxy information statement and proxy card, http://www.streetinsider.com/Press+Releases/Eagle+Pharmaceuticals+Announces+Availability+of+Proxy+Materials+and+Audited+Financial+Statements+for+the+2023+and+2024+Fiscal+Years/25346502.html Wed, 17 Sep 2025 16:43:00 -0500 EGRX O.00073296 http://www.streetinsider.com/Press+Releases/Eagle+Pharmaceuticals+Announces+Availability+of+Proxy+Materials+and+Audited+Financial+Statements+for+the+2023+and+2024+Fiscal+Years/25346502.html <p align="justify">WOODCLIFF LAKE, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced the availability of proxy materials for its 2025 Annual Meeting of Stockholders, which is scheduled to be held virtually on October 17, 2025 at 10:00 a.m. Eastern Time.</p> <p align="justify">The Company is delivering a Notice of Internet Availability of Proxy Materials (“Notice”) to stockholders of record as of the close of business on August 18, 2025. The proxy materials relating to the 2025 Annual Meeting of Stockholders, including the Notice, proxy information statement and proxy card, http://www.streetinsider.com/Press+Releases/Eagle+Pharmaceuticals+Announces+Availability+of+Proxy+Materials+and+Audited+Financial+Statements+for+the+2023+and+2024+Fiscal+Years/25346502.html Wed, 17 Sep 2025 16:43:00 -0500 EGRX O.00073296 http://www.streetinsider.com/Globe+Newswire/Eagle+Pharmaceuticals+Announces+Availability+of+Proxy+Materials+and+Audited+Financial+Statements+for+the+2023+and+2024+Fiscal+Years/25346502.html <p align="justify">WOODCLIFF LAKE, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced the availability of proxy materials for its 2025 Annual Meeting of Stockholders, which is scheduled to be held virtually on October 17, 2025 at 10:00 a.m. Eastern Time.</p> <p align="justify">The Company is delivering a Notice of Internet Availability of Proxy Materials (“Notice”) to stockholders of record as of the close of business on August 18, 2025. The proxy materials relating to the 2025 Annual Meeting of Stockholders, including the Notice, proxy information statement and proxy card, http://www.streetinsider.com/Globe+Newswire/Eagle+Pharmaceuticals+Announces+Availability+of+Proxy+Materials+and+Audited+Financial+Statements+for+the+2023+and+2024+Fiscal+Years/25346502.html Wed, 17 Sep 2025 16:43:00 -0500 EGRX O.00073296 http://www.streetinsider.com/Globe+Newswire/Eagle+Pharmaceuticals+Announces+Availability+of+Proxy+Materials+and+Audited+Financial+Statements+for+the+2023+and+2024+Fiscal+Years/25346502.html <p align="justify">WOODCLIFF LAKE, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced the availability of proxy materials for its 2025 Annual Meeting of Stockholders, which is scheduled to be held virtually on October 17, 2025 at 10:00 a.m. Eastern Time.</p> <p align="justify">The Company is delivering a Notice of Internet Availability of Proxy Materials (“Notice”) to stockholders of record as of the close of business on August 18, 2025. The proxy materials relating to the 2025 Annual Meeting of Stockholders, including the Notice, proxy information statement and proxy card, http://www.streetinsider.com/Globe+Newswire/Eagle+Pharmaceuticals+Announces+Availability+of+Proxy+Materials+and+Audited+Financial+Statements+for+the+2023+and+2024+Fiscal+Years/25346502.html Wed, 17 Sep 2025 16:43:00 -0500 EGRX O.00073296 http://www.streetinsider.com/Board+Changes/Eagle+Pharmaceuticals+appoints+Abhinav+Jain+to+board+of+directors/25271271.html <p>Eagle Pharmaceuticals Inc. (OTCMKTS: EGRX) announced it will appoint Abhinav Jain as an independent member of its board of directors, subject to customary onboarding procedures. The appointment follows a cooperation agreement with Nantahala Capital Management LLC, which holds approximately 38% of Eagle's outstanding shares.</p> <p>Jain will serve as a Class III director with an initial term expiring at the company's 2026 annual meeting of stockholders. He will serve on the board's compensation committee and nominating and corporate governance committee.</p> <p>Under the cooperation agreement, Eagle also committed to appoint a second new independent director to the board no later than May 15, 2026. http://www.streetinsider.com/Board+Changes/Eagle+Pharmaceuticals+appoints+Abhinav+Jain+to+board+of+directors/25271271.html Thu, 28 Aug 2025 19:30:53 -0500 A.03350906 A.03607790 A.31066700 A.31711001 A.50200961 A.50202612 EGRX O.00073296 O.00134964 O.01868273 O.20147506 http://www.streetinsider.com/Board+Changes/Eagle+Pharmaceuticals+appoints+Abhinav+Jain+to+board+of+directors/25271271.html <p>Eagle Pharmaceuticals Inc. (OTCMKTS: EGRX) announced it will appoint Abhinav Jain as an independent member of its board of directors, subject to customary onboarding procedures. The appointment follows a cooperation agreement with Nantahala Capital Management LLC, which holds approximately 38% of Eagle's outstanding shares.</p> <p>Jain will serve as a Class III director with an initial term expiring at the company's 2026 annual meeting of stockholders. He will serve on the board's compensation committee and nominating and corporate governance committee.</p> <p>Under the cooperation agreement, Eagle also committed to appoint a second new independent director to the board no later than May 15, 2026. http://www.streetinsider.com/Board+Changes/Eagle+Pharmaceuticals+appoints+Abhinav+Jain+to+board+of+directors/25271271.html Thu, 28 Aug 2025 19:30:53 -0500 A.03350906 A.03607790 A.31066700 A.31711001 A.50200961 A.50202612 EGRX O.00073296 O.00134964 O.01868273 O.20147506 http://www.streetinsider.com/Board+Changes/Eagle+Pharmaceuticals+appoints+Abhinav+Jain+to+board+of+directors/25271271.html <p>Eagle Pharmaceuticals Inc. (OTCMKTS: EGRX) announced it will appoint Abhinav Jain as an independent member of its board of directors, subject to customary onboarding procedures. The appointment follows a cooperation agreement with Nantahala Capital Management LLC, which holds approximately 38% of Eagle's outstanding shares.</p> <p>Jain will serve as a Class III director with an initial term expiring at the company's 2026 annual meeting of stockholders. He will serve on the board's compensation committee and nominating and corporate governance committee.</p> <p>Under the cooperation agreement, Eagle also committed to appoint a second new independent director to the board no later than May 15, 2026. http://www.streetinsider.com/Board+Changes/Eagle+Pharmaceuticals+appoints+Abhinav+Jain+to+board+of+directors/25271271.html Thu, 28 Aug 2025 19:30:53 -0500 A.03350906 A.03607790 A.31066700 A.31711001 A.50200961 A.50202612 EGRX O.00073296 O.00134964 O.01868273 O.20147506 http://www.streetinsider.com/Board+Changes/Eagle+Pharmaceuticals+appoints+Abhinav+Jain+to+board+of+directors/25271271.html <p>Eagle Pharmaceuticals Inc. (OTCMKTS: EGRX) announced it will appoint Abhinav Jain as an independent member of its board of directors, subject to customary onboarding procedures. The appointment follows a cooperation agreement with Nantahala Capital Management LLC, which holds approximately 38% of Eagle's outstanding shares.</p> <p>Jain will serve as a Class III director with an initial term expiring at the company's 2026 annual meeting of stockholders. He will serve on the board's compensation committee and nominating and corporate governance committee.</p> <p>Under the cooperation agreement, Eagle also committed to appoint a second new independent director to the board no later than May 15, 2026. http://www.streetinsider.com/Board+Changes/Eagle+Pharmaceuticals+appoints+Abhinav+Jain+to+board+of+directors/25271271.html Thu, 28 Aug 2025 19:30:53 -0500 A.03350906 A.03607790 A.31066700 A.31711001 A.50200961 A.50202612 EGRX O.00073296 O.00134964 O.01868273 O.20147506 http://www.streetinsider.com/Board+Changes/Eagle+Pharmaceuticals+appoints+Abhinav+Jain+to+board+of+directors/25271271.html <p>Eagle Pharmaceuticals Inc. (OTCMKTS: EGRX) announced it will appoint Abhinav Jain as an independent member of its board of directors, subject to customary onboarding procedures. The appointment follows a cooperation agreement with Nantahala Capital Management LLC, which holds approximately 38% of Eagle's outstanding shares.</p> <p>Jain will serve as a Class III director with an initial term expiring at the company's 2026 annual meeting of stockholders. He will serve on the board's compensation committee and nominating and corporate governance committee.</p> <p>Under the cooperation agreement, Eagle also committed to appoint a second new independent director to the board no later than May 15, 2026. http://www.streetinsider.com/Board+Changes/Eagle+Pharmaceuticals+appoints+Abhinav+Jain+to+board+of+directors/25271271.html Thu, 28 Aug 2025 19:30:53 -0500 A.03350906 A.03607790 A.31066700 A.31711001 A.50200961 A.50202612 EGRX O.00073296 O.00134964 O.01868273 O.20147506 http://www.streetinsider.com/Board+Changes/Eagle+Pharmaceuticals+appoints+Abhinav+Jain+to+board+of+directors/25271271.html <p>Eagle Pharmaceuticals Inc. (OTCMKTS: EGRX) announced it will appoint Abhinav Jain as an independent member of its board of directors, subject to customary onboarding procedures. The appointment follows a cooperation agreement with Nantahala Capital Management LLC, which holds approximately 38% of Eagle's outstanding shares.</p> <p>Jain will serve as a Class III director with an initial term expiring at the company's 2026 annual meeting of stockholders. He will serve on the board's compensation committee and nominating and corporate governance committee.</p> <p>Under the cooperation agreement, Eagle also committed to appoint a second new independent director to the board no later than May 15, 2026. http://www.streetinsider.com/Board+Changes/Eagle+Pharmaceuticals+appoints+Abhinav+Jain+to+board+of+directors/25271271.html Thu, 28 Aug 2025 19:30:53 -0500 A.03350906 A.03607790 A.31066700 A.31711001 A.50200961 A.50202612 EGRX O.00073296 O.00134964 O.01868273 O.20147506 http://www.streetinsider.com/Board+Changes/Eagle+Pharmaceuticals+appoints+Abhinav+Jain+to+board+of+directors/25271271.html <p>Eagle Pharmaceuticals Inc. (OTCMKTS: EGRX) announced it will appoint Abhinav Jain as an independent member of its board of directors, subject to customary onboarding procedures. The appointment follows a cooperation agreement with Nantahala Capital Management LLC, which holds approximately 38% of Eagle's outstanding shares.</p> <p>Jain will serve as a Class III director with an initial term expiring at the company's 2026 annual meeting of stockholders. He will serve on the board's compensation committee and nominating and corporate governance committee.</p> <p>Under the cooperation agreement, Eagle also committed to appoint a second new independent director to the board no later than May 15, 2026. http://www.streetinsider.com/Board+Changes/Eagle+Pharmaceuticals+appoints+Abhinav+Jain+to+board+of+directors/25271271.html Thu, 28 Aug 2025 19:30:53 -0500 A.03350906 A.03607790 A.31066700 A.31711001 A.50200961 A.50202612 EGRX O.00073296 O.00134964 O.01868273 O.20147506 http://www.streetinsider.com/Board+Changes/Eagle+Pharmaceuticals+appoints+Abhinav+Jain+to+board+of+directors/25271271.html <p>Eagle Pharmaceuticals Inc. (OTCMKTS: EGRX) announced it will appoint Abhinav Jain as an independent member of its board of directors, subject to customary onboarding procedures. The appointment follows a cooperation agreement with Nantahala Capital Management LLC, which holds approximately 38% of Eagle's outstanding shares.</p> <p>Jain will serve as a Class III director with an initial term expiring at the company's 2026 annual meeting of stockholders. He will serve on the board's compensation committee and nominating and corporate governance committee.</p> <p>Under the cooperation agreement, Eagle also committed to appoint a second new independent director to the board no later than May 15, 2026. http://www.streetinsider.com/Board+Changes/Eagle+Pharmaceuticals+appoints+Abhinav+Jain+to+board+of+directors/25271271.html Thu, 28 Aug 2025 19:30:53 -0500 A.03350906 A.03607790 A.31066700 A.31711001 A.50200961 A.50202612 EGRX O.00073296 O.00134964 O.01868273 O.20147506 http://www.streetinsider.com/Board+Changes/Eagle+Pharmaceuticals+appoints+Abhinav+Jain+to+board+of+directors/25271271.html <p>Eagle Pharmaceuticals Inc. (OTCMKTS: EGRX) announced it will appoint Abhinav Jain as an independent member of its board of directors, subject to customary onboarding procedures. The appointment follows a cooperation agreement with Nantahala Capital Management LLC, which holds approximately 38% of Eagle's outstanding shares.</p> <p>Jain will serve as a Class III director with an initial term expiring at the company's 2026 annual meeting of stockholders. He will serve on the board's compensation committee and nominating and corporate governance committee.</p> <p>Under the cooperation agreement, Eagle also committed to appoint a second new independent director to the board no later than May 15, 2026. http://www.streetinsider.com/Board+Changes/Eagle+Pharmaceuticals+appoints+Abhinav+Jain+to+board+of+directors/25271271.html Thu, 28 Aug 2025 19:30:53 -0500 A.03350906 A.03607790 A.31066700 A.31711001 A.50200961 A.50202612 EGRX O.00073296 O.00134964 O.01868273 O.20147506 http://www.streetinsider.com/Board+Changes/Eagle+Pharmaceuticals+appoints+Abhinav+Jain+to+board+of+directors/25271271.html <p>Eagle Pharmaceuticals Inc. (OTCMKTS: EGRX) announced it will appoint Abhinav Jain as an independent member of its board of directors, subject to customary onboarding procedures. The appointment follows a cooperation agreement with Nantahala Capital Management LLC, which holds approximately 38% of Eagle's outstanding shares.</p> <p>Jain will serve as a Class III director with an initial term expiring at the company's 2026 annual meeting of stockholders. He will serve on the board's compensation committee and nominating and corporate governance committee.</p> <p>Under the cooperation agreement, Eagle also committed to appoint a second new independent director to the board no later than May 15, 2026. http://www.streetinsider.com/Board+Changes/Eagle+Pharmaceuticals+appoints+Abhinav+Jain+to+board+of+directors/25271271.html Thu, 28 Aug 2025 19:30:53 -0500 A.03350906 A.03607790 A.31066700 A.31711001 A.50200961 A.50202612 EGRX O.00073296 O.00134964 O.01868273 O.20147506 http://www.streetinsider.com/Board+Changes/Eagle+Pharmaceuticals+appoints+Abhinav+Jain+to+board+of+directors/25271271.html <p>Eagle Pharmaceuticals Inc. (OTCMKTS: EGRX) announced it will appoint Abhinav Jain as an independent member of its board of directors, subject to customary onboarding procedures. The appointment follows a cooperation agreement with Nantahala Capital Management LLC, which holds approximately 38% of Eagle's outstanding shares.</p> <p>Jain will serve as a Class III director with an initial term expiring at the company's 2026 annual meeting of stockholders. He will serve on the board's compensation committee and nominating and corporate governance committee.</p> <p>Under the cooperation agreement, Eagle also committed to appoint a second new independent director to the board no later than May 15, 2026. http://www.streetinsider.com/Board+Changes/Eagle+Pharmaceuticals+appoints+Abhinav+Jain+to+board+of+directors/25271271.html Thu, 28 Aug 2025 19:30:53 -0500 A.03350906 A.03607790 A.31066700 A.31711001 A.50200961 A.50202612 EGRX O.00073296 O.00134964 O.01868273 O.20147506 http://www.streetinsider.com/Press+Releases/Eagle+Pharmaceuticals+to+Appoint+Abhinav+Jain+to+its+Board+of+Directors/25271269.html <p align="justify">WOODCLIFF LAKE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that it has agreed to appoint Abhinav “Abi” Jain as an independent member of its Board of Directors, subject to customary onboarding procedures. Mr. Jain will be a Class III director with an initial term expiring at the Company’s 2026 Annual Meeting of Stockholders and serve on the Board’s Compensation Committee and Nominating and Corporate Governance Committee. In connection with Mr. Jain’s planned appointment, Eagle entered into a cooperation agreement (the “Agreement”) with Nantahala Capital Management, LLC http://www.streetinsider.com/Press+Releases/Eagle+Pharmaceuticals+to+Appoint+Abhinav+Jain+to+its+Board+of+Directors/25271269.html Thu, 28 Aug 2025 19:30:00 -0500 A.03350906 A.03607790 A.31066700 A.31711001 A.50200961 A.50202612 EGRX O.00073296 O.00134964 O.01868273 O.20147506 http://www.streetinsider.com/Press+Releases/Eagle+Pharmaceuticals+to+Appoint+Abhinav+Jain+to+its+Board+of+Directors/25271269.html <p align="justify">WOODCLIFF LAKE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that it has agreed to appoint Abhinav “Abi” Jain as an independent member of its Board of Directors, subject to customary onboarding procedures. Mr. Jain will be a Class III director with an initial term expiring at the Company’s 2026 Annual Meeting of Stockholders and serve on the Board’s Compensation Committee and Nominating and Corporate Governance Committee. In connection with Mr. Jain’s planned appointment, Eagle entered into a cooperation agreement (the “Agreement”) with Nantahala Capital Management, LLC http://www.streetinsider.com/Press+Releases/Eagle+Pharmaceuticals+to+Appoint+Abhinav+Jain+to+its+Board+of+Directors/25271269.html Thu, 28 Aug 2025 19:30:00 -0500 A.03350906 A.03607790 A.31066700 A.31711001 A.50200961 A.50202612 EGRX O.00073296 O.00134964 O.01868273 O.20147506 http://www.streetinsider.com/Press+Releases/Eagle+Pharmaceuticals+to+Appoint+Abhinav+Jain+to+its+Board+of+Directors/25271269.html <p align="justify">WOODCLIFF LAKE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that it has agreed to appoint Abhinav “Abi” Jain as an independent member of its Board of Directors, subject to customary onboarding procedures. Mr. Jain will be a Class III director with an initial term expiring at the Company’s 2026 Annual Meeting of Stockholders and serve on the Board’s Compensation Committee and Nominating and Corporate Governance Committee. In connection with Mr. Jain’s planned appointment, Eagle entered into a cooperation agreement (the “Agreement”) with Nantahala Capital Management, LLC http://www.streetinsider.com/Press+Releases/Eagle+Pharmaceuticals+to+Appoint+Abhinav+Jain+to+its+Board+of+Directors/25271269.html Thu, 28 Aug 2025 19:30:00 -0500 A.03350906 A.03607790 A.31066700 A.31711001 A.50200961 A.50202612 EGRX O.00073296 O.00134964 O.01868273 O.20147506 http://www.streetinsider.com/Press+Releases/Eagle+Pharmaceuticals+to+Appoint+Abhinav+Jain+to+its+Board+of+Directors/25271269.html <p align="justify">WOODCLIFF LAKE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that it has agreed to appoint Abhinav “Abi” Jain as an independent member of its Board of Directors, subject to customary onboarding procedures. Mr. Jain will be a Class III director with an initial term expiring at the Company’s 2026 Annual Meeting of Stockholders and serve on the Board’s Compensation Committee and Nominating and Corporate Governance Committee. In connection with Mr. Jain’s planned appointment, Eagle entered into a cooperation agreement (the “Agreement”) with Nantahala Capital Management, LLC http://www.streetinsider.com/Press+Releases/Eagle+Pharmaceuticals+to+Appoint+Abhinav+Jain+to+its+Board+of+Directors/25271269.html Thu, 28 Aug 2025 19:30:00 -0500 A.03350906 A.03607790 A.31066700 A.31711001 A.50200961 A.50202612 EGRX O.00073296 O.00134964 O.01868273 O.20147506 http://www.streetinsider.com/Press+Releases/Eagle+Pharmaceuticals+to+Appoint+Abhinav+Jain+to+its+Board+of+Directors/25271269.html <p align="justify">WOODCLIFF LAKE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that it has agreed to appoint Abhinav “Abi” Jain as an independent member of its Board of Directors, subject to customary onboarding procedures. Mr. Jain will be a Class III director with an initial term expiring at the Company’s 2026 Annual Meeting of Stockholders and serve on the Board’s Compensation Committee and Nominating and Corporate Governance Committee. In connection with Mr. Jain’s planned appointment, Eagle entered into a cooperation agreement (the “Agreement”) with Nantahala Capital Management, LLC http://www.streetinsider.com/Press+Releases/Eagle+Pharmaceuticals+to+Appoint+Abhinav+Jain+to+its+Board+of+Directors/25271269.html Thu, 28 Aug 2025 19:30:00 -0500 A.03350906 A.03607790 A.31066700 A.31711001 A.50200961 A.50202612 EGRX O.00073296 O.00134964 O.01868273 O.20147506